National Institute of Diabetes and Digestive and Kidney Diseases

RFA-DK-20-022 Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS)

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)

Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-945-7573

Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov

Scientific/Research Contact(s)

For Division of Digestive Diseases and Nutrition-related inquiries:

Peter J. Perrin, Ph.D.

National Institute of Diabetes and Digestive and Kidney Diseases

1950 70 years 2020

Background

- Research on HIV comorbidities, coinfections, and complications is an NIH HIV research priority
  - Antiretroviral therapy (ART) does not improve CCCs
  - Chronic infection, long term ART use and aging all contribute to CCCs
- Important CCCs fall within NIDDK's mission
  - Enteropathy and disruption of GI homeostasis, noncommunicable liver disease and viral hepatitis
  - Kidney, urologic, and hematologic diseases
  - Obesity, diabetes, associated complications
  - NIDDK-relevant processes may contribute to HIV pathogenesis in other tissues
- Underlying biological mechanisms in the setting of HIV

Purpose

To support multidisciplinary research teams with complementary expertise in in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the NIDDK. These teams will comprehensively interrogate fundamental mechanisms underlying HIV-associated CCCs relevant to the mission of the NIDDK.

Examples of Topic Areas

- Pathophysiological and metabolic pathways where HIV or its treatment contribute to CCCs in NIDDK's mission
- Interaction of HIV or its treatment with biological processes within NIDDK's mission
  - Metabolism, endocrine function, erythrocyte biology and hematopoiesis, development and progression of kidney disease, GI mucosal homeostasis
- Impact of HIV or its treatment on the GI or penile microbiome, pathogenic enteric microbes, male genital tract infections, or viral hepatitis co-infection
- Response of tissues within NIDDK's mission to HIV and HIV-associated inflammation

RFA-DK-20-022: MPI Structure Required

- Requires a Multiple PD/PI structure
  - At least one PD/PI with expertise in HIV science
  - At least one PD/PI with expertise in physiology, pathobiology, pathobiology and/or metabolism
  - May include additional expertise as required
  - Projects lacking this structure will be withdrawn and not reviewed
- Previous publications or extensive collaboration not expected

RFA-DK-20-022: Additional Instructions

Approach:

- Include a brief description of each PD/PI's contribution to the preliminary data with its presentation
  - Design, execution, or interpretation

Multiple PD/PI Leadership Plan:

- Include one or more examples of how development of specific aspects of the research plan benefited from interactions between the PDs /PIs.
- Describe how each PD/PI will participate in aspects of the project primarily led by the other PD(s)/PI(s)
  - How will the combined expertise of the Multiple PD/PI team be leveraged?

Note: There are corresponding review criteria

RFA-DK-20-022

- Nonresponsive projects:
  - One or more components ineligible for the use of HIV/AIDS-designated funds
  - Do not use MPI format
  - Clinical trials designed to answer questions about the clinical effect of an intervention
  - Rely primarily on epidemiological approaches
  - Projects that deal predominantly with HIV reservoirs
  - Studies primarily focused on HIV CCCs outside of the NIDDK's mission

RFA-DK-20-022

RFA-DK-20-022: Toward ElucidAting MechanismS Contributing to HIV Reservoirs in NIDDK-relevant Tissues (Cure TEAMS) (R01 Clinical Trial Optional)

Trans-NIDDK RFA

Issued: September 2, 2020

Due: March 3, 2021

Council: October 2021

Due: November 17, 2021

Council: May 2022

Budget max: $500,000 DC/year

Duration max: 5 years

$3M/year (5-6 awards)

Resubmission (A1) applications are allowed for the November 2021 receipt. A0 must have been submitted to RFA-DK-20-023

Frequently Asked Questions

- Can I include a substantial component, such as and Aim or sub-Aim, addressing related mechanisms that do not include HIV or its treatment?
  - No, the RFA requires that 100% of the research plan addresses NIH priority research and is eligible for the use of HIV/AIDS-designated funds
- Can the Multiple PD/PI team consist of individuals who have published previously?
  - Yes, Although previous collaboration is not expected, it is allowed
- Is a study addressing the impact of a CCC on the HIV reservoir appropriate?
  - It depends. If a project's primary focus is on how a CCC effects the HIV reservoir, it is not responsive, and you should consider RFA-DK-20-023. If the overall focus is on mechanisms of CCC initiation or progression, you may include studies on the reservoir related to your overarching hypothesis.

Please type in your questions using the Q&A tool to ask questions (access at the bottom of your screen)

Questions will be answered verbally